We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BioTrove and SPRI Expand Lead Discovery Collaboration
News

BioTrove and SPRI Expand Lead Discovery Collaboration

BioTrove and SPRI Expand Lead Discovery Collaboration
News

BioTrove and SPRI Expand Lead Discovery Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BioTrove and SPRI Expand Lead Discovery Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

BioTrove has announced an expansion of its collaboration with Schering-Plough Research Institute, the research arm of Schering-Plough Corporation.

As part of the ongoing relationship, BioTrove will use its proprietary RapidFire® Lead Discovery service for assay development and high throughput screening on an undisclosed number of targets identified by Schering-Plough.

RapidFire Lead Discovery is a mass spectrometry-based technology that enables the high throughput screening of biochemical assays.

The system can analyze assays by mass spectrometry at throughputs of four to eight seconds per sample.

"With RapidFire our collaborators have been able to pursue many drug targets that were previously inaccessible due to technical or economical difficulties," said Can "Jon" Ozbal, Ph.D., Director of the RapidFire program.

"The ability of RapidFire to perform direct mass spectrometric quantification of native substrates and products facilitates very fast assay development by eliminating the need to synthesize and validate surrogate substrates or antibodies for conventional optical assays," he added.

"We are pleased with the expansion of our ongoing relationship with Schering-Plough."

"The growing level of interest and novel findings from our pharmaceutical partners validates our unique position in the area of high throughput screening," said Alan Carter, Chief of Commercial Operations.

Advertisement